이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

AI-Assisted Management of Pulmonary Nodules Found on Low-Dose CT in Health Screening (AI-NoduleCare)

2026년 9월 20일 업데이트: Jianxing He, The First Affiliated Hospital of Guangzhou Medical University

Clinical Utility of Artificial Intelligence-Assisted Management Decisions for Pulmonary Nodules Detected by Low-Dose Computed Tomography in Health Screening: A Multicenter, Prospective, Cluster-Randomized Controlled Trial

Pulmonary nodules are frequently found during low-dose computed tomography (LDCT) health screening. The main challenge is not only detecting nodules, but also recommending the appropriate next step, such as routine follow-up, short-interval imaging follow-up, or specialist evaluation. This multicenter cluster-randomized trial will evaluate whether an artificial intelligence (AI)-assisted reporting workflow improves the appropriateness of pulmonary nodule management decisions in health examination settings without increasing under-management or missed referrals. Participating health examination branches, rather than individual participants, will be randomly assigned in a 1:1 ratio to a conventional reporting workflow or an AI-assisted reporting workflow. All final reports will be reviewed and signed by qualified physicians. An independent expert endpoint committee, blinded to study assignment and AI output, will determine the acceptable management range for each case. Approximately 2,000 adults with pulmonary nodules detected on LDCT will be included across at branches.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

2000

단계

  • 해당 없음

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age 18 years or older.
  • Undergoing chest low-dose computed tomography at a participating health examination branch during the study recruitment period.
  • At least one pulmonary nodule is identified on the index LDCT and requires risk stratification and a management decision regarding follow-up, repeat imaging, or specialist evaluation.
  • Thin-section reconstructed images are of sufficient quality for clinical interpretation and, where applicable, AI analysis.
  • Required clinical risk information is available, including age, sex, smoking history, history of malignancy, family history of lung cancer, and available prior chest imaging.
  • Included under the ethics committee-approved consent, simplified notification, waiver, and/or opt-out process, with no documented refusal of research data use.

Exclusion Criteria:

  • Previously diagnosed lung cancer or currently receiving lung cancer-related treatment.
  • Known pulmonary metastasis from another malignancy.
  • Imaging findings that clearly require immediate entry into a lung cancer specialty diagnostic or treatment pathway and are not appropriate for routine pulmonary nodule risk-stratified management.
  • An urgent thoracic condition requiring immediate management, such as pneumothorax, large pleural effusion, or acute pulmonary embolism.
  • Severe imaging artifact, incompatible slice thickness or reconstruction, or a lesion type, imaging parameter, or disease extent outside the prespecified locked scope of the AI system.
  • Previous enrollment in this study.
  • Explicit refusal of research data use, or another reason judged by the investigator to make inclusion inappropriate.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 상영
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: AI-Assisted Pulmonary Nodule Reporting Workflow

Physicians first record and lock an initial pulmonary nodule management decision without viewing AI results. They then review locked-version AI outputs, including nodule characteristics, estimated malignancy risk, and a management recommendation, and issue the final physician-signed report. Physicians may accept, modify, or reject the AI recommendation. The AI cannot automatically sign reports or directly instruct participants.

A locked-version artificial intelligence decision-support workflow applied after the physician records an initial assessment. The system displays pulmonary nodule location, size, density, morphologic features, estimated malignancy risk, and a suggested management category. The physician retains final responsibility. If the system fails, times out, or produces an abnormal output, the case returns to manual reporting. No online learning or automatic model updating is allowed during the trial.

활성 비교기: Conventional Pulmonary Nodule Reporting Workflow

Physicians interpret LDCT examinations and issue pulmonary nodule management recommendations using the participating branch's conventional clinical reporting workflow. Study AI output is not displayed.

Standard manual LDCT interpretation and pulmonary nodule management recommendation by qualified physicians using the participating branch's routine reporting process, without access to study AI output.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of Participants With an Appropriate Final Management Recommendation
기간: At the index LDCT report (Day 0)

Percentage of evaluable participants whose final physician recommendation is within the acceptable management range determined by the blinded independent expert endpoint committee. Recommendations are classified as routine or annual follow-up, short-interval imaging follow-up, or specialist evaluation/referral. The expert committee will complete adjudication using index data within approximately 30 days, but the participant-level outcome is the recommendation made at Day 0.

At the index LDCT report (Day 0)

2차 결과 측정

결과 측정
측정값 설명
기간
Proportion of Participants With Under-Management
기간: At the index LDCT report (Day 0)

Percentage of evaluable participants whose final physician recommendation is less intensive than the minimum acceptable management level determined by the blinded independent expert endpoint committee.

At the index LDCT report (Day 0)
Proportion of Expert-Defined Referral Cases Missed by the Final Report
기간: At the index LDCT report (Day 0)

Among participants whom the blinded independent expert endpoint committee determines require specialist evaluation/referral, the percentage whose final physician report does not recommend specialist evaluation/referral. The denominator includes only expert-defined referral cases.

At the index LDCT report (Day 0)
Proportion of Participants With Inappropriate Management Escalation
기간: At the index LDCT report (Day 0)

Percentage of evaluable participants whose final physician recommendation is more intensive than the maximum acceptable management level determined by the blinded independent expert endpoint committee.

At the index LDCT report (Day 0)
Change in Decision Appropriateness After AI Review in the AI-Assisted Arm
기간: At the index LDCT report (Day 0)

In the AI-assisted arm, the physician's locked pre-AI decision will be compared with the final post-AI decision against the same expert-accepted management range. Results will include: (1) correction rate, the number changing from inappropriate to appropriate divided by the number with an inappropriate pre-AI decision; (2) AI-induced error rate, the number changing from appropriate to inappropriate divided by the number with an appropriate pre-AI decision; and (3) net correction rate, calculated as (number corrected minus number made incorrect) divided by all evaluable participants in the AI-assisted arm. These denominators must be locked in the statistical analysis plan before database lock.

At the index LDCT report (Day 0)
Physician Response to the AI Recommendation
기간: During the index LDCT reporting session (Day 0)

Time in minutes from the start of physician image review to final report completion, as recorded by the reporting platform or study system.

During the index LDCT reporting session (Day 0)
Proportion of AI-Assisted Cases With System Failure
기간: During the index LDCT reporting session (Day 0)

Percentage of eligible cases in the AI-assisted arm for which the AI system does not return a usable output because of processing failure, timeout, technical incompatibility, or an output meeting the prespecified abnormal-output fallback criteria.

During the index LDCT reporting session (Day 0)
Proportion of Participants With a Pulmonary Nodule-Related Management Action Within 90 Days
기간: 90 days after the index LDCT examination (allowable window, ±14 days)

Percentage of participants with at least one documented pulmonary nodule-related management action during follow-up, including specialist evaluation, repeat chest CT, contrast-enhanced CT, PET-CT, biopsy, or surgery. Each component will also be summarized separately. Information will be obtained from available routine records, participant-provided records, or ethics-approved telephone follow-up.

90 days after the index LDCT examination (allowable window, ±14 days)
Proportion of Participants With a Reporting-Workflow-Related Management or Data Security Adverse Event
기간: From the index LDCT report through 90 days after the index examination (allowable window, ±14 days)

Percentage of participants with a prespecified event potentially related to the assigned reporting workflow, including missed or substantially delayed evaluation of a high-risk nodule, an unnecessary invasive procedure, hospitalization or major psychological/economic burden caused by an erroneous recommendation, or a serious data security event. Serious events will also be reported according to applicable ethics and institutional requirements.

From the index LDCT report through 90 days after the index examination (allowable window, ±14 days)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 1일

기본 완료 (추정된)

2028년 3월 1일

연구 완료 (추정된)

2028년 12월 31일

연구 등록 날짜

최초 제출

2026년 9월 20일

QC 기준을 충족하는 최초 제출

2026년 9월 20일

처음 게시됨 (실제)

2026년 9월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 25일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 20일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • AI-NC-2026-01

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .